TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 6.18nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 22.5nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 23.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 30.9nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 61.8nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 67nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 104nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 116nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 123nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 189nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 214nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 293nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 298nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 330nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 344nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 388nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: 435nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair
TargetCyclin-dependent kinase 6/G1/S-specific cyclin-D1(Homo sapiens (Human))
Shengke Pharmaceuticals (Jiangsu)
US Patent
Shengke Pharmaceuticals (Jiangsu)
US Patent
Affinity DataIC50: >500nMAssay Description:Compounds of the present disclosure were tested in a 10-dose IC50 mode with a 3-fold serial dilution starting from 0.5 μM, and the control compo...More data for this Ligand-Target Pair